IND stage candidate for the treatment of neuropathic pain

KD7040 is a potent, topically administered, inhibitor of inducible nitric oxide synthase (iNOS) with greater than 200-fold and 2000-fold selectivity over nNOS and eNOS respectively.

KD7040 demonstrates robust reduction of tactile allodynia in rodent models of pain, including the Chung model (peripheral neuropathy), the Bennet chronic constrictive injury model, and the capsaicin model of central sensitization. Preliminary data from GLP safety pharmacology and toxicology studies have defined a favorable safety profile for entry into the clinic.

Kalypsys is currently targeting a 4Q06 IND submission.

KD7040 Fact Sheet